Mycobacterium avium-M. intracellulare, a common opportunistic pathogen in HIV-infected patients, is a leading cause of death in patients with AIDS (1, 2, 6, 7, 9, 10) . Public Health Service (4) recommends treating M. avium-M. intracellulare-infected patients with a macrolide, either clarithromycin or azithromycin, in combination with rifabutin and/or ethambutol. Monotherapy prophylaxis with clarithromycin or azithromycin is recommended for HIV-infected patients with a CD4 ϩ cell count of Ͻ50 cells/l. Recent findings suggest a greater microbiological response with clarithromycin than that with azithromycin when these agents are used either as monotherapy or in combination (3, 4, 13) . Ward and colleagues found that the combination of clarithromycin-ethambutol cleared M. avium-M. intracellulare bacteremia in a significantly higher percentage of HIV-infected patients compared to azithromycin-ethambutol (87.5 versus 37.5% [P ϭ 0.007]), with clearance occurring significantly faster (4.4 versus Ͼ16 weeks, [P ϭ 0.0018]) (13). Our study evaluated the in vitro MICs of clarithromycin and azithromycin against M. avium-M. intracellulare.
